Department of Ophthalmology

Experts in Eye Care

Pioneers in Research

Leaders in Academics
The Department of Ophthalmology at SUNY Downstate Medical Center has a well-established history of accomplishment as an educator of physicians. The program's reputation as a center of research excellence has blossomed in the last few years, and our clinical service provides state-of-the-art care to residents of the Brooklyn community.

In assessing the potential of our ophthalmology program in Brooklyn, a comparison is instructive. SUNY Downstate's catchment area contains a population of approximately 685,000—roughly equal to that of the city of Boston. In 1996, the residents of Boston were served by 250 practicing ophthalmologists; in contrast, SUNY Downstate's catchment area had only eight. This paucity of ophthalmologists had historically motivated many Brooklynites to turn to Manhattan physicians for eye care, as evidenced by the fact that 30 to 40 percent of ophthalmology patients treated in Manhattan lived in Brooklyn. This trend has stopped as our faculty practice now boasts 18 UOC (University Ophthalmic Consultants) doctors who span all disciplines within ophthalmology and provide the most advanced care for the most complicated disease states.

These facts point to both an opportunity and an urgent need. The goals we have attained have promoted Brooklyn as a desirable practice environment for faculty physicians and residents-in-training. We have enthusiastically committed ourselves to providing desperately needed care for the many community residents with glaucoma, retinopathy of diabetes, and other disorders that are potentially blinding or that otherwise diminish their quality of life. Our faculty and residents come from all over the United States and we are fortunate to have many graduates of the program involved in many aspects of the teaching program after completing their training.

The department has been fortunate to win support and funding from the SUNY Downstate leadership and our affiliated clinical practice sites. This, in turn, has allowed for the recruitment of first-rate faculty. Single individuals are made responsible for each of six subspecialty programs networkwide, and many faculty members rotate among the sites. This approach has permitted us to keep faculty fully occupied and challenged while extending the benefits of their special abilities to patients at several institutions. Additionally, we have purchased advanced diagnostic technologies in all subspecialty areas, allowing for the management of complex disease. In 2010, we added additional faculty in Retina and Oculoplastics who will work at both Downstate in the faculty practice, and at Kings County Hospital Center with residents.

Our faculty, plus our improved facilities and expanded clinical offerings, have, indeed, dramatically increased demand for ophthalmology services. At our largest clinical affiliate, Kings County Hospital, outpatient visits have increased significantly year after year over the last decade, and leadership has provided a wonderful opportunity for growth of our service in both the clinic and the operating room. We relocated to a modern 9,500 square feet Eye Clinic in Kings County in 2006 due to continued growth of the service, which now provides EMR, networked digital image analysis at the work station, simulated cataract training, and a minor procedure room in this state-of-the-art facility.

We have similarly expanded the faculty practice facility at Downstate, known as The Midwood Eye Center, located conveniently on Nostrand Avenue near the junction of Flatbush Avenue. This impressive facility boasts 16 exam rooms in addition to multiple other diagnostic and treatment areas.

Our eye research program has vastly grown in the basic science area. Long known for excellence in clinical research, we now are deeply committed to the study of various eye diseases at the cellular level, and our PhD scientists are working feverishly to find cures for eye disease. With many basic and clinical studies currently underway, I am proud to have led this significant expansion of research at Downstate, along with my Director of Research, William Brunken, PhD, one of the world’s authorities on retinal extracellular matrix proteins.

We currently have National Eye Institute funding in addition to extramural grant support to help with our research endeavors. Ophthalmology residents and medical students have been fully integrated into our research program and actively participate in all phases of our studies. Furthermore, we have been leaders in the conception and formation of the SUNY Eye Institute, a statewide consortium of many of the top eye researchers across the state from SUNY’s four academic medical centers and SUNY Optometry, which allows us to cross-train and teach, collaborate on projects, and at the same time share important resources.

Many other details of our program—and their positive results—are described in the report that follows. Suffice it to say that our diverse and expert faculty, plus our improved facilities and expanded clinical and research offerings, have dramatically increased demand for ophthalmology services in Brooklyn. We are poised to meet the challenge and serve as leaders in the field.

DOUGLAS R. LAZZARO, MD, FACS, FAAO
Professor and Chairman
The Richard C. Troutman, MD, Distinguished Chair in Ophthalmology and Ophthalmic Microsurgery
Leaders in Eye Care

The State University of New York Downstate Medical Center has a rich tradition in medical education, research and clinical care, dating back to 1860 when Long Island College Hospital became the first medical school in the United States to include bedside teaching in the curriculum.

The Division of Ophthalmology was formally instituted in 1873. Today, the Department of Ophthalmology employs state-of-the-art procedures to provide both adult and pediatric patients with the best possible care for a broad range of ocular disorders.

Basic and Clinical Research

The Department of Ophthalmology has a long and distinguished history of research contributions in the field of ophthalmology. Current faculty continues that tradition as they employ cutting-edge technology in research projects that enhance our understanding of the structure, function and disorders of the eye and visual system. A particular focus of current research is the determination of the etiology, pathophysiology and treatment of eye diseases across ethnic boundaries.

Vision researchers at SUNY Downstate Medical Center are a multidisciplinary group of cell, molecular and developmental biologists, as well as clinical scientists. We join research efforts across departmental boundaries—ophthalmology, cell biology, neurology and pediatrics—forming a cohesive collaboration that addresses the clinical needs of Brooklyn, Queens and Staten Island. Our investigators include faculty, residents, and medical and graduate students who meet regularly to discuss their work as well as that of others.

Our outstanding facilities for basic science and clinical research and treatment all feature modern, state-of-the-art equipment. At Downstate there are a number of dedicated eye research laboratories in addition to other labs, where eye and other areas of cell biology research are being conducted simultaneously. A new animal facility is under construction at Downstate and will be opening shortly. The very significant expansion of vision research conducted on campus has led to National Eye Institute funding and other public and private funding.

Our large residency training program and faculty practice gives us the ability to examine a very diverse group of patients exhibiting the entire spectrum of eye disease. This allows us to perform clinical studies and, in addition, should give us an unprecedented opportunity to bring translational science to future clinical applications.

Collaboration

Collaborative teams of basic and clinical scientists are working hard to advance our understanding of eye disease.

- Dr. William Brunken’s group is interested in the role of laminins in eye development and disease. Their recent paper, published in Investigative Ophthalmology & Visual Science, shows that disruptions of laminins can cause congenital retinal disease. Dr. Brunken is funded by the NEI.

- Dr. John Danias was awarded a new grant of $500,000 from the National Eye Institute to study steroid-induced glaucoma. Long-term steroid treatment can provoke glaucoma, and Dr. Danias, along with Dr. Oscar Candia of Mount Sinai Medical School, is studying the molecular and genetic changes caused by steroid use in the eye to better understand how to avoid these complications.

- Dr. William Brunken and Dr. Oscar Candia teamed up to study the role of the extracellular matrix in ocular disease and repair. Their recent presentation at the International Association for Research in Vision and Ophthalmology demonstrated that laminins and integrins regulate corneal epithelial proliferation.

- Dr. Brabim Chaqour has teamed up with clinicians to address the role of extracellular matrix molecules in regulating vascular development. Their paper, published in Endocrinology, details how components of the ECM lead to blood vessel remodeling. Dr. Chaqour is funded by the NEI.

- Dr. Douglas Lazzaro and Dr. William Brunken have teamed up to study the role of the extracellular matrix in corneal disease and repair. Their recent presentation at the International Association for Research in Vision and Ophthalmology demonstrated that laminins and integrins regulate corneal epithelial proliferation.

- Dr. Ivan Bodis-Wollner heads a team of neurologists, ophthalmologists and basic scientists studying the retinal effects of Parkinson’s Disease. Their recent article in Archives of Ophthalmology demonstrates retinal thinning in persons with Parkinson’s disease. Dr. Bodis-Wollner is funded by the Michael J. Fox Foundation for Parkinson’s Research.
Clinical Services

Set your sights high.
We do.

- Comprehensive Ophthalmology
- Cornea and External Disease Service
- Corneal Refractive Surgery / Laser Vision Surgery / Intacs Implants
- Contact Lens Services
- Dry Eye Service
- Glaucoma Service
- Neuro-Ophthalmology Service
- Oculoplastics / Orbital Service
- Retina Service
- Pediatric Ophthalmology & Strabismus Service
- Ocular Imaging Service
- Urgent Care Center

Comprehensive Consultative Ophthalmology

The University Ophthalmic Consultant’s comprehensive ophthalmologists can diagnose and treat most ocular disorders. When more advanced diagnosis or treatment is indicated, they will refer patients to one of UOC's outstanding subspecialists. The Consultative Service’s board-certified physicians perform a complete range of examinations, with appropriate diagnostic tests, and treat conditions such as myopia, infectious and allergic conjunctivitis, and cataracts. Our comprehensive physicians screen for diabetic retinopathy and also perform anterior segment surgery, such as cataract extractions. Referring physicians are sent expedited consult letters so necessary treatments can begin without delay.

Contact Us
For further information, or to make a referral or schedule an appointment, please call:
University Hospital of Brooklyn (718) 270-1714
Long Island College Hospital (718) 780-1530
Bay Ridge (718) 748-1334

Physician Staff
Kichiemon Asoma, MD – UHB, LICH
Michael Ehrenhaus, MD – UHB, LICH
Himani Goyal, MD – Bay Ridge
Douglas Lazzaro, MD – Bay Ridge, LICH
Bradley Phillips, MD – UHB

Dry Eye Service

More than six million Americans suffer from dry eyes, and the number of symptomatic individuals is increasing as our population ages. For the dry eye patient, early evaluation and treatment is important to prevent ocular surface damage before it occurs, as well as to relieve patient discomfort.

Typically, lid function, lacrimal system function and the conjunctival surfaces all play a role in the development of dry eye conditions. Successful treatment depends on complete evaluation of the patient and potential treatment modalities based on the specific etiology identified. Ocular lubricants are the mainstays of therapy, but punctal occlusion, repositioning of the eyelids or, occasionally, conjunctival transplants may be indicated.

Because a patient's work or lifestyle can exacerbate dry eye symptoms, our experts often prescribe a daily regimen specifically tailored to control his or her condition.

Contact Us
For further information, or to make a referral or schedule an appointment, please call:
University Hospital of Brooklyn (718) 270-1714
Long Island College Hospital (718) 780-1530
Bay Ridge (718) 748-1334

Physician Staff
Kichiemon Asoma, MD – UHB, LICH
Michael Ehrenhaus, MD – UHB, LICH
Himani Goyal, MD – Bay Ridge
Douglas Lazzaro, MD – Bay Ridge, LICH

Glaucoma Service

Several ethnic groups in the Brooklyn community suffer a high incidence of various forms of glaucoma. The UOC Glaucoma Service offers state-of-the-art technology to detect glaucoma-related diseases, and its dedicated, culturally sensitive physicians offer a wide range of treatment modalities. Glaucoma management and free community screenings are important aspects of our service.

Extensive patient evaluation is required for the effective treatment and management of glaucoma in its many forms. A full range of highly advanced medical tests is available to patients through UOC’s Ocular Imaging Service and Ocular Blood Flow Service. Precise measurement of ocular blood flow is particularly important to the accurate evaluation of...
normal tension glaucoma. This test also allows clinicians to gauge the effects of therapy on blood flow to the eye.

Management of high-risk glaucoma is among our service’s specialties. Potential treatments include filtering surgery with antibiotics, placement of aqueous drainage shunts, and various combined procedures. Many treatments are performed in collaboration with the UOC Cornea and Retina Service.

The Glaucoma Service also offers a multidisciplinary approach to anterior segment reconstruction. Services are available by appointment, and urgent consultations are always available.

Contact Us
For further information, or to make a referral or schedule an appointment, please call:
Long Island College Hospital (718) 780-1530
University Hospital of Brooklyn (718) 270-1714

Physician Staff
Bradley Phillips, MD – UHB, LICH
Lekha Gopal, MD – LICH
Wayne Scott, MD – UHB, LICH

Retina Service
The UOC Retina Service offers comprehensive medical and surgical management for a large variety of retinal conditions which include diabetic retinopathy, macular degeneration, epiretinal membranes, macular holes, retinal detachment, proliferative vitreoretinopathy, non-diabetic vascular diseases, and AIDS-related retinopathies.

The service maintains a fully-equipped retina surgical suite and an operating room equipped to manage all retinal surgical conditions. All instruments are state-of-the-art and fully up to date with the latest technology.

Diagnostic Testing
The Retina Service is equipped to provide:
- Spectral domain optical coherence tomography (SDOCT)
- Stereo fundus photography
- Digital fluorescein angiography
- ICG angiography
- B-scan ultrasonography
- Heidelberg retina tomography/flowmeter
- Heidelberg retinal angiography

Contact Us
For further information, or to make a referral or schedule an appointment, please call:
Long Island College Hospital (718) 780-1530
University Hospital of Brooklyn (718) 270-1714

Physician Staff
Kenneth Olumba, MD – UHB, LICH
Eric Shrier, MD – UHB, LICH

Oculoplastics/Orbit Service
The Oculoplastics/Orbit Service evaluates and treats patients at both University Hospital of Brooklyn and Long Island College Hospital. Expedited consultations are available when necessary.

The service has particular expertise in thyroid ophthalmopathy and traumatic orbital fractures, and our surgeons also treat a wide range of other conditions. Commonly performed surgeries include lid and orbital oculoplastic procedures for tumors, infections and inflammatory conditions. Following a comprehensive evaluation, required corrective procedures are performed in a timely way. As soon as it is medically appropriate, patients are returned to the care of their referring physician.

Operating facilities of the Oculoplastics/Orbit Service support a broad range of eyelid and orbital surgeries. The majority of lid surgeries are performed under local anesthesia in the minor surgery suite of either University Hospital or Long Island College Hospital. Unless medically indicated, no pre-testing is needed for such procedures. More complex surgery is performed in a standard operating suite under monitored or general anesthesia. Except in rare circumstances, patients are discharged on the day of surgery.

Contact Us
For further information, or to make a referral or schedule an appointment, please call:
Long Island College Hospital (718) 780-1530
University Hospital of Brooklyn (718) 270-1714

Physician Staff
John Danias, MD, PhD – LICH
Jeffrey Freedman, MD, PhD – UHB
Shobit Rastogi, MD – UHB, LICH
Wayne Scott, MD – UHB, LICH

Pediatric Ophthalmology and Strabismus Service
The Pediatric Ophthalmology and Strabismus Service specializes in the medical and surgical treatment of eye muscle misalignment in children and adults. In addition, this service provides comprehensive care for all ocular disorders in children, including the treatment of amblyopia, tear duct obstruction, ocular infections, pediatric cataracts, and eye problems associated with arthritis, genetic disorders, premature birth or neurologic disease.

Service physicians evaluate and treat children with:
- Congenital nystagmus or early-onset nystagmus
- Congenital or genetic ocular abnormalities
- Systemic syndromes, metabolic disorders or chromosomal abnormalities, including:
  - Juvenile rheumatoid arthritis
  - Galactosemia
  - Diabetes mellitus
  - Marfan’s syndrome
  - Down’s syndrome
  - Retinopathy of prematurity
  - Ocular or periorcular infection/inflammation
  - Congenital ptosis or eyelid hemangiomas
  - Poor vision or delayed attainment of vision
  - Congenital or childhood cataracts
  - Strabismus (eye misalignment)
  - Amblyopia

Service physicians are also available for optical or surgical correction of eye misalignment and double vision in adults with a history of childhood strabismus, thyroid eye disease / Grave’s disease, myasthenia gravis, nerve palsies, or a history of ocular trauma.

Contact Us
For further information, or to make a referral or schedule an appointment, please call:
Long Island College Hospital (718) 780-1530
University Hospital of Brooklyn (718) 270-1714

Physician Staff
James Deutsch, MD – LICH
Ashima Kumar, MD – UHB, LICH

Ocular Imaging Service
The Ocular Imaging Service aids in the diagnosis of a wide range of ocular disorders by providing physicians with comprehensive, highly detailed images of structures within the eye. Sophisticated ocular images typically are used to formulate a more effective treatment plan. Ocular imaging is also used to detect plateau iris syndrome or a partially dislocated lens.

At the referring physician’s request, UOC ocular imaging test reports can include a complete evaluation by a UOC consultant, or images can be submitted to the referring physician without interpretation.
Available Tests

- **Ultrasonic Biomicroscopy** – Ultrasound biomicroscopy (UBM) to evaluate the chamber angle without medication in a dark versus light room is the methodology of choice for determining if an angle is occludable after iridectomy (in plateau iris syndrome). UBM can also be used to determine if an angle is occludable after iridectomy (in plateau iris syndrome). Biomicroscopy has proven increasingly useful for defining anterior segment pathology in patients with complex disease. Ultrasound biomicroscopy is available for imaging pathologic structure and physiologic abnormalities in the anterior segment with a resolution of 50 microns. Use includes identification and location of intraocular lens haptics, location of glaucoma drainage tubes, vitreous strands, determining the integrity of scleral wounds, and locating inadvertent filtration blebs and cyclodialysis clefts. Using biomicroscopy to evaluate these and many other abnormalities allows the implementation of more exact modalities.

- **Corneal Pachymetry** – Studies have shown that abnormal corneal thickness can lead to a false high or low intraocular pressure reading as well as independent high or low mal corneal thickness can lead to a false high or low pressure.

- **Disc Topography - OCT and Heidelberg Retinal Optical Coherence Topography** – Computerized c:d ratio, rim area and cup area for comparison to a normative database and future self-comparative analysis. This instrument is currently considered the most reliable available for disc analysis. It also measures nerve fiber layer thickness.

- **Nerve Fiber Layer Measurement** – Measurement of nerve fiber layer thickness is performed with the NFA/GDs scanning laser polarimeter, as well as with Heidelberg retinal tomography (HRT). Testing is completed in seconds and may document changes in nerve fiber layer thickness in very early disease, as well as in advanced optic atrophy with extensive cupping or pallor. This test is useful in glaucoma suspects, as well as in patients with documented glaucoma and other causes of optic neuropathy. Pupil dilation is not necessary. The HRT unit provides a full threshold, 24-3, 30-2, and customized testing available upon request.

- **Optical Coherence Topography** – Measurement of retinal lesions and thicknesses are profiled by this state-of-the-art imaging system.

- **Visual Field Testing** – Frequency Doubling Perimetry (FTD) has been shown to be the most sensitive test for detecting the initial defects caused by glaucoma. In addition, both conventional automated visual field testing and blue-on-yellow (SWAP) visual field testing are available. SWAP (short wave automated perimeter) testing demonstrates visual field loss as many as five years earlier than conventional testing, and it is more sensitive in detecting advancing visual field changes. Screening, full threshold, 24-3, 30-2, and customized testing are available upon request.

- **Gonioscopy** – ICG angiography

- **Fluorescein angiography**

- **Digital fluorescein angiography**

- **Confocal and Specular Biomicroscopy**

- **OCT** – Optical Coherence Tomography – Computerized c:d ratio, rim area and cup area for comparison to a normative database and future self-comparative analysis. This instrument is currently considered the most reliable available for disc analysis. It also measures nerve fiber layer thickness.

- **Corneal Pachymetry** – Studies have shown that abnormal corneal thickness can lead to a false high or low intraocular pressure reading as well as independent high risk factor for progressive disease. Using appropriate nomograms, corneal thickness measurements can be used to obtain a closer approximation of the true intraocular pressure.

- **Ultrasound Biomicroscopy** – Ultrasound biomicroscopy (UBM) to evaluate the chamber angle without medication in a dark versus light room is the methodology of choice for determining if an angle is physiologically occludable.

To Schedule a Test

Tests should be scheduled through University Hospital of Brooklyn or Long Island College Hospital (see contact information below). On the day of the test, referred patients must bring with them a completed request form. Forms will be faxed to referring physician offices upon request.

Contact Us

For further information, or to make a referral or schedule an appointment, please call:

- Long Island College Hospital (718) 780-1530
- University Hospital of Brooklyn (718) 270-1714

Urgent Care Center

Emergency eye care is available from 8:00 am to 6:00 pm in the ophthalmology departments of both University Hospital of Brooklyn and Long Island College Hospital.

In addition, emergency eye care is available 24 hours a day through the Department of Ophthalmology’s Urgent Care Center, also at both Long Island College Hospital and University Hospital of Brooklyn.

Patients presenting at either location will be seen initially by an ophthalmologist resident who is in direct consultation with an on-call ophthalmology attending physician.

Referring Physician Contact

The ophthalmologists of non-referred patients are called by the resident/attending at the time of the patient visit. For referred patients, referring physicians will also be notified of patient results the same evening of the patient’s emergency visit, if possible. If not, they will be contacted the following morning.

Contact Information

Patients or their physicians may request urgent eye care at either location by calling (718) 780-2600, 24 hours a day, 7 days a week, including all holidays.

Urgent Eye Care, University Hospital of Brooklyn

445 Lenox Road, Box 58
Brooklyn, NY 11203

(718) 270-1714

Urgent Eye Care Center at Long Island College Hospital

Othmer Building, 4th Floor, 339 Hicks Street
Brooklyn, NY 11201

To Schedule a Test

Tests should be scheduled through University Hospital of Brooklyn or Long Island College Hospital (see contact information below). On the day of the test, referred patients must bring with them a completed request form. Forms will be faxed to referring physician offices upon request.

Contact Us

For further information, or to make a referral or schedule an appointment, please call:

- Long Island College Hospital (718) 780-1530
- University Hospital of Brooklyn (718) 270-1714

Urgent Care Center

Emergency eye care is available from 8:00 am to 6:00 pm in the ophthalmology departments of both University Hospital of Brooklyn and Long Island College Hospital.

In addition, emergency eye care is available 24 hours a day through the Department of Ophthalmology’s Urgent Care Center, also at both Long Island College Hospital and University Hospital of Brooklyn.

Patients presenting at either location will be seen initially by an ophthalmologist resident who is in direct consultation with an on-call ophthalmology attending physician.

Referring Physician Contact

The ophthalmologists of non-referred patients are called by the resident/attending at the time of the patient visit. For referred patients, referring physicians will also be notified of patient results the same evening of the patient’s emergency visit, if possible. If not, they will be contacted the following morning.

Contact Information

Patients or their physicians may request urgent eye care at either location by calling (718) 780-2600, 24 hours a day, 7 days a week, including all holidays.

Urgent Eye Care, University Hospital of Brooklyn

445 Lenox Road, Box 58
Brooklyn, NY 11203

(718) 270-1714

Urgent Eye Care Center at Long Island College Hospital

Othmer Building, 4th Floor, 339 Hicks Street
Brooklyn, NY 11201

Practice Locations

SUNY Downstate Medical Center
University Hospital of Brooklyn
450 Clarkson Avenue, Box 58
Brooklyn, NY 11203
Phone (718) 270-1714

Midwood
SUNY Downstate Eye Center
2171 Nostrand Avenue @ Flatbush
Brooklyn, NY 11210
Phone (718) 270-1714

Long Island College Hospital
Othmer Building
339 Hicks Street, 4th Floor
Brooklyn, NY 11201
Phone (718) 780-1530

Bay Ridge
7901 4th Avenue
Brooklyn, NY 11209
Phone (718) 748-1334

Brooklyn Heights
110 Remsen Street
Brooklyn, NY 11201
Phone (718) 585-8700

Manhattan
229 East 79th Street
New York, NY 10075
Phone (212) 288-0905

Laser Vision Correction Center
SUNY Downstate at Bay Ridge
699 92nd Street
Brooklyn, NY 11228
Phone (718) 748-1334

For further information, or to make a referral or schedule an appointment, please call:

- Long Island College Hospital (718) 780-1530
- University Hospital of Brooklyn (718) 270-1714
Dr. Richard Troutman headed the Department of Ophthalmology at Downstate from 1955 to 1983. In 2002, The Richard C. Troutman Distinguished Chair in Ophthalmology and Ophthalmic Microsurgery was initiated at SUNY Downstate Medical Center with a $1 million gift from the Microsurgical Research Foundation. The endowment was completed by 2005 with an additional $1 million. The Chair honors the foundation’s legendary founder, Dr. Richard C. Troutman, a worldwide leader in ophthalmic microsurgery and one of the innovators in the design of the ophthalmic microscope.

The Troutman Chair in Ophthalmology

Dr. Troutman is a member and past officer of many ophthalmic specialty societies, including the prestigious American Ophthalmological Society, founded in 1864. In 1978, when his wife Dr. Suzanne Véronneau-Troutman was admitted as the 8th woman member, they became the first couple in the history of the society.

To contribute to the Richard C. Troutman, MD, Distinguished Chair in Ophthalmology and Ophthalmic Microsurgery Endowment Fund, please call Downstate’s Department of Institutional Advancement and Philanthropy at 718-270-4418. If you prefer, you may also donate online at: http://www.downstate.edu/giving/ways.html

Dr. Troutman celebrating his birthday with his wife Dr. Suzanne Véronneau-Troutman on May 16, 2008

Laser Vision Correction Center

A brand new, state-of-the-art laser center has been established due to the generosity of Dr. Richard C. Troutman and his wife, Dr. Suzanne Véronneau. Dr. Troutman has left a long-lasting imprint on the field of ophthalmic microsurgery that continues today.

The Laser Vision Correction Center is located at SUNY Downstate at Bay Ridge. We offer both LASIK and PRK procedures. For appointments call 718-748-1334.

VISX STAR S4 Excimer Laser System with WaveScan

WaveScan technology captures unique imperfections in each individual’s vision that could not have been measured before. This new level of measurement provides 25 times more precision than measurements using standard methods for glasses and contact lenses. WaveScan technology produces a detailed map of the eye—much like a fingerprint, no two are alike—and translates this information into a set of CustomVue treatment instructions for the laser. WaveScan transfers these digital treatment instructions to the laser, providing a new level of precision and accuracy.
In June of 1955, Dr. Troutman was appointed as the first Professor and Head of the Division of Ophthalmology at the newly opened SUNY Downstate Medical Center. He had completed his residency in Ophthalmology at CUMC (New York Hospital Cornell Medical Center) under John McLean in 1951. Until his appointment, he was Instructor to Residents at MEETH (Manhattan Eye Ear and Throat Hospital) and served as Assistant Professor of Ophthalmology at CUMC. It was at that time he began his pioneering developments in ophthalmic microsurgery by modifying a Zeiss ophthalmic microscope for use in anterior segment surgery. He soon realized that before the better visualization through the microscope could be utilized effectively, extensive changes in instrumentation, needles and suture materials, as well as in the microscope itself, would have to be made before its full potential could be realized.

His first priority, however, was the development of the new division. Fortunately, the National Institutes of Health (NIH) had recently inaugurated its Ophthalmology Training Grant program that provided support for Dr. Robert Jampel and Dr. Bernard Schwartz with their specialty training in strabismus and glaucoma, both of whom joined the full-time faculty. The further addition of specialized part-time faculty made possible this specialty-based training program, one of the first of its kind in the country, with 12 residents and 4 fellows. This group of residents and fellows were the first trained to use the microscope for their anterior segment surgery.

In 1957, Dr. Troutman designed and had constructed at Downstate the first hydraulic, chair-supported ophthalmic surgical microscope for use in the operating suite.

Two years later, in 1959, Dr. Troutman invited Dr. Joaquin Barraquer, who was travelling in Latin America demonstrating his surgery, to SUNY. He, too, was using a microscope that he had developed with his brother José. They also developed specialized microsurgical instruments, in particular, a new suture material, 8-0 virgin silk armed with a 5mm Grishabel needle, which was far superior to those being used in the US at the time. Dr. Troutman immediately incorporated this for his surgery and advocated the same to many of his colleagues.

In 1962, Dr. Troutman, with the Keeler Instrument Company, developed and used the first remote-controlled, motorized, zoom-magnification microscope for ophthalmic microsurgery.

That same year, Dr. Barraquer discovered alphachymotrypsin, an enzyme that facilitated the intracapsular extraction of cataract, and sent some to Dr. Troutman to try. Suitably impressed, he convinced the AAOS to sponsor a national trial of its safety and efficacy, based at SUNY, and that resulted in its worldwide acceptance. This technique went unchallenged until extracapsular extraction and phacoemulsification (for which Dr. Troutman chaired a similar trial for the AAOS in 1975) became the procedures of choice for cataract surgery. These studies and the Courses in Microsurgery held at SUNY and at the AAO, and taught by our residents, faculty and foreign guests, put our program “on the map.”

Meanwhile, Dr. Troutman continued his development of surgical microscopes, introducing the first motorized zoom microscope (Keeler) in 1962 and his ceiling mounted microscope with XYZ translation and focusing and planetary tilt (Keck) in 1967, concepts that continue to be used in contemporary surgical microscopes by many specialties.

In 1966, to further the development of ophthalmic microsurgery, with Günther Mackensen and Heinrich Harms of the Universität Tübingen in Germany he formed the IOMSG (International Ophthalmic Surgery Study Group). In 1963 they had introduced him to 10-0 monofilament nylon that significantly improved corneal wound closure, but was unknown outside their institution. Dr. Troutman subsequently made 10-0 nylon universally available through the Ethicon Suture Division of J&J, as chair of the AAOS Suture Committee in the United States.

In 1967, Dr. Troutman developed, in conjunction with the Week Surgical Company, the first ceiling-mounted zoom ophthalmic surgical microscope that incorporated remotely controlled focusing and centering, planetary tilting and multi-focal illumination. Contemporary surgical microscopes that incorporate Dr. Troutman’s concepts continue to be the instruments of choice for ophthalmic microsurgery.

Inert in tissue and elastic, 10-0 nylon suture could hold the cornea firmly in apposition for months, allowing first intention healing which prevented the optical changes in the cornea from tissue displacement. Using Dr. Troutman’s corneal wedge resection it was possible for the first time to correct severe astigmatism post keratoplasty, and for lesser degrees with his corneal relaxing incisions (1975), the first effective, reproducible refractive keratoplasty procedures.

It was at the first IOMSG meeting that Dr. Troutman met José Barraquer. Because of their mutual interests in refractive keratoplasty, they developed a close relationship that would lead Dr. Troutman to perform the first lamellar refractive surgeries outside Colombia, keratoplasty and keratomileusis in 1977, after he and his Corneal Fellow Dr. Casimir Swinger were trained in the technique by Dr. Barraquer in Bogotá. Two years later, at a meeting of the New Orleans Academy of Ophthalmology featuring Dr. Barraquer, Dr. Troutman and Dr. Swinger reported their early results which would lead to safer, more effective refractive surgical techniques. With Dr. Miles Friedlander, they formed the ISRS (International Society of Refractive Surgery) which has become the primary forum for this specialty and is the first international specialty to be recognized by the AAOS and included in its annual program.

At SUNY Downstate, Dr. Troutman’s Division of Ophthalmology postgraduate training program was one of the first in the United States to routinely teach microsurgery of the eye to its residents.

Dr. Troutman has authored or co-authored 7 textbooks, many book chapters and more than 150 scientific publications, many of which detail his interests and innovations in microsurgical techniques and instrumentation for anterior segment surgery. In recognition of his pioneering advances, he has been recognized with numerous awards, citations and named lectureships. He is a member and past officer of many ophthalmic specialty societies, including the prestigious American Ophthalmological Society, founded in 1864. In 1978, when his wife Dr. Suzanne Véronneau-Troutman was admitted as the 8th woman member, they became the first couple in the history of the society.

In 2000, Dr. Troutman received the Lifetime Achievement Award from the American Academy of Ophthalmology for “many years of distinguished service to the society.” He is one of the first seven ophthalmologists to have received this award from the AAOS.

Dr. Richard C. Troutman is a worldwide leader in ophthalmic microsurgery and one of the innovators in the design of the ophthalmic microscope.
The department currently provides a three-year postgraduate training program for 21 residents, with seven new candidates accepted each year. Residents benefit from the wisdom of a large, expert faculty with a deep commitment to teaching, and they have the opportunity to work with the latest diagnostic and therapeutic equipment. The organized teaching program consists of approximately 350 hours of didactic lectures per residency, covering all subspecialty areas within ophthalmology. On one afternoon a week, residents leave the clinic areas and report to Downstate for an afternoon of grand rounds case presentations followed by didactics. Special program features include a one-week course in San Antonio for first year residents and a one-week Wills Review course for second-year residents, while third year residents attend an approved course of their choice. In addition, all residents attend a weekly, three-hour cooperative course collaboratively sponsored by several major New York City-based residency training programs. The SUNY Downstate program offers outstanding training in surgery, with in-house courses for strabismus, glaucoma surgery, vitrectomy and cataract techniques. All residents easily exceed the minimum surgical requirements set by the Accreditation Commission for Graduate Medical Education (ACGME). It is expected that the senior residents will all perform more than 120 cataract cases. A comparable experience is gained in ocular trauma, glaucoma surgery, retinal surgery and laser surgery.

The program includes monthly faculty grand rounds, often with visiting professors, updating residents and faculty on developing trends and techniques in ophthalmology, in addition to the weekly resident grand rounds. All residents must execute a research project, and mentorships are established in the first year of residency training. Other special program features include an oncology rotation at Memorial Sloan-Kettering and small group eye pathology teaching sessions.

Particularly popular with residents is the surgical course, with outstanding practice opportunities under expert faculty guidance. Strengths of the overall residency program, they say, include the extensive exposure to trauma cases it provides, and its well-structured rotations through programs at the various affiliated hospitals beginning in the first year. This gets residents off to a positive start through experience with a variety of patients and pathologies. Another outstanding aspect of the SUNY Downstate education program, according to residents and fellows, is the opportunity it affords them to work and learn in state-of-the-art facilities, where the most sophisticated equipment permits conducting the most advanced procedures. They also praise the dynamism of the faculty and the program’s emphasis on research accomplishment. Approximately 96 percent of the program’s graduate residents pass their boards on the first attempt, and many who have sought fellowships have obtained prestigious ones throughout the US. Some graduates who have decided to remain in Brooklyn to practice are discovering a vast, barely tapped market for professional eye care. There has been a marked increase in the quality of applicants for residency program openings over the last decade, apparently attracted by the department’s growing reputation nationally. At its most recent review by the ACGME in 2009, the department received a full four-year accreditation.

- Largest residency program in the New York City area.
- Most diverse patient population in the nation.
- Eight residency training sites.
- Experienced, diverse faculty.
- High surgical volume.
- Wide breadth of pathology.
- Over 100,000 patients seen annually.
<table>
<thead>
<tr>
<th>Graduates 2009</th>
<th>Fellowship</th>
<th>PL3 Class 2011-2012</th>
<th>Medical School Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Habeeb Ahmed</td>
<td>Cornea - University of Southern California</td>
<td>Dr. Sara Ferri</td>
<td>SUNY Buffalo</td>
</tr>
<tr>
<td>Dr. Kichiemon Asoma</td>
<td>Cornea - University of Texas Southwestern Medical Center</td>
<td>Dr. Sara Hanson</td>
<td>Boston University School of Medicine</td>
</tr>
<tr>
<td>Dr. Carl Danzig</td>
<td>Retina - University of Texas Southwestern Medical Center</td>
<td>Dr. Amy Kulak</td>
<td>University of Miami School of Medicine</td>
</tr>
<tr>
<td>Dr. Majida Gaffar</td>
<td>Pediatric Ophthalmology - Children's National Medical Center, Washington</td>
<td>Dr. Akil Pascal</td>
<td>SUNY Downstate</td>
</tr>
<tr>
<td>Dr. Adam Jacobowitz</td>
<td>Uveitis - Johns Hopkins College of Medicine</td>
<td>Dr. Gabriel Schaab</td>
<td>Rush Medical College</td>
</tr>
<tr>
<td>Dr. Na Ma</td>
<td>Neuro-Ophthalmology/Plastics - Kingsbrook/SUNY Downstate</td>
<td>Dr. Melanie Sobel</td>
<td>Drexel College of Medicine</td>
</tr>
<tr>
<td>Dr. Preeti Poley</td>
<td>Retina - University of Nebraska</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Kirk Sturridge</td>
<td>Glaucoma - University of Iowa</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Graduates 2010</td>
<td>Fellowship</td>
<td>PL2 Class 2011-2012</td>
<td>Medical School Attended</td>
</tr>
<tr>
<td>Dr. Rodney Coe</td>
<td>Retina - University of Pittsburgh</td>
<td>Dr. Cindy Calderer</td>
<td>SUNY Stony Brook</td>
</tr>
<tr>
<td>Dr. Gennifer Greebal</td>
<td>Pediatric Ophthalmology - Children's National Medical Center, Washington</td>
<td>Dr. Justin Gutman</td>
<td>SUNY Upstate</td>
</tr>
<tr>
<td>Dr. Sheetal Patel</td>
<td>Cornea - Cornell Medical Center</td>
<td>Dr. David Mostafavi</td>
<td>University of Medicine and Dentistry of New Jersey</td>
</tr>
<tr>
<td>Dr. Allison Rand</td>
<td>Cornea - Mount Sinai Medical Center</td>
<td>Dr. Chirantan Mukhopadhyay</td>
<td>University of Wisconsin School of Medicine</td>
</tr>
<tr>
<td>Dr. Marjorie Rico</td>
<td>Oculoplastics - Dr. Janet Neigel</td>
<td>Dr. Sherry Narang</td>
<td>Drexel College of Medicine</td>
</tr>
<tr>
<td>Dr. Brandon Rodriguez</td>
<td>Cornea - Cornell Medical Center</td>
<td>Dr. David Rand</td>
<td>University of Miami School of Medicine</td>
</tr>
<tr>
<td>Dr. Jeremy Shaw</td>
<td>Medical Retina - Duke University Medical Center</td>
<td>Dr. Isaac Reich</td>
<td>SUNY Downstate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Shetel Shah</td>
<td>SUNY Downstate</td>
</tr>
<tr>
<td>Graduates 2011</td>
<td>Fellowship</td>
<td>PL1 Class 2011-2012</td>
<td>Medical School Attended</td>
</tr>
<tr>
<td>Dr. Ramanath Bhandari</td>
<td>Retina - University of Colorado</td>
<td>Dr. Matthew Gorski</td>
<td>Jefferson College of Medicine</td>
</tr>
<tr>
<td>Dr. John Frisbee</td>
<td>Retina - The Ochsner Foundation</td>
<td>Dr. Jason Moss</td>
<td>Stanford College of Medicine</td>
</tr>
<tr>
<td>Dr. Andrew Greenberg</td>
<td>Glaucoma - NY Eye and Ear Infirmary</td>
<td>Dr. Renelle Pintaudjour</td>
<td>SUNY Downstate</td>
</tr>
<tr>
<td>Dr. Alex Karvelishvili</td>
<td>Retina - Valley Retina Institute Texas</td>
<td>Dr. Allison Rizzuti</td>
<td>SUNY Downstate</td>
</tr>
<tr>
<td>Dr. Margaret Liu</td>
<td>Cornea - Johns Hopkins School of Medicine</td>
<td>Dr. Jordan Spindle</td>
<td>Texas A &amp; M College of Medicine</td>
</tr>
<tr>
<td>Dr. Monika Singh</td>
<td>Private Practice</td>
<td>Dr. Adam Thode</td>
<td>Jefferson College of Medicine</td>
</tr>
<tr>
<td>Dr. Beatrice Whitaker</td>
<td></td>
<td>Dr. Frank Tsai</td>
<td>Temple College of Medicine</td>
</tr>
<tr>
<td>Dr. Lauren Yeager</td>
<td>Pediatric Ophthalmology - Children's National Medical Center, Washington</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The Department of Ophthalmology is committed to the educational needs of the community ophthalmologist. To that end, a comprehensive Visiting Clinical Lecture series takes place along with a Research Lecture series as a component of the Thursday Grand Rounds Series.

In addition to this widely popular activity, there are two large symposia each year that bring together some of the world’s top clinical scientists to share their knowledge on their particular specialty. The meetings cover a very wide area of ophthalmology and focus on the diagnostic testing and emerging therapies for eye disease.

The 2-day symposium has taken place at Caesars Atlantic City the past four years and attracted attendees from seven states.

The two-day January symposium has taken place at Caesars Atlantic City in New Jersey the past four years and has attracted attendees from seven states. It takes place on a Friday and Saturday, generally around the second weekend of the month. This scientific and social venue has become an excellent place for returning attendees each year, many of whom have commented that this is “the best CME event I have attended in my career.”

The June one-day meeting occurs in Brooklyn as part of the annual Alumni Meeting and is held on the first or second Thursday of the month. Past and future CME events can be viewed at www.eyecurrentconcepts.org.

The 2-day symposium has taken place at Caesars Atlantic City the past four years and attracted attendees from seven states.

The June one-day meeting occurs in Brooklyn as part of the annual Alumni Meeting and is held on the first or second Thursday of the month. Past and future CME events can be viewed at www.eyecurrentconcepts.org.
“I had the pleasure of participating in SUNY Downstate’s Current Concepts in Ophthalmology meeting in Atlantic City in January 2010 and was highly impressed with the outstanding reputation and quality of the invited speakers, the clinical relevance of the superb presentations, the wonderful setting, and Dr. Douglas Lazzaro’s remarkable hospitality and organizational skills as the course director. This is truly one of the country’s outstanding continuing medical education experiences.”

— Gregory L. Skuta, MD
President and Chief Executive Officer
Dean McGee Eye Institute
Edward L. Gaylord Professor and Chair
Department of Ophthalmology
University of Oklahoma College of Medicine
The SUNY Downstate Department of Ophthalmology is proud to present our 2011 Visiting Speaker Lecture Series, a forum for renowned clinicians and researchers to present their latest findings. These lectures will feature advances in many areas of clinical ophthalmology and ophthalmic research, presented by noted clinical and basic scientists from throughout the world. Ample opportunity will be provided for questions and answers.

Most programs will be held in Lecture Hall 1A, SUNY Downstate Medical Center, in the afternoon. For your convenience, there is valet parking at the main entrance of University Hospital of Brooklyn, 445 Lenox Road.

Please join us for these insights into ophthalmic research and the promises they hold for patient care.

No registration is required.

Department of Ophthalmology

Visiting Speaker Lecture Series

Lecture Series

Course Directors

Douglas R. Lazzaro, MD, FACS, FAAO
Professor and Chair of Ophthalmology
Richard C. Troutman, MD, Distinguished Chair
In Ophthalmology and Ophthalmic Microsurgery
Chief of Service: UHB, KCHC

William J. Brunken, BS, PhD
Director of Ophthalmic Research
Professor of Ophthalmology and Cell Biology
VISITING SPEAKER CLINICAL LECTURE SERIES 2011

January 13, 2011
2:00-4:00 PM, Lecture Hall 1A
Jeanine K. Suchecki, MD
Associate Professor of Ophthalmology
University of Connecticut School of Medicine
Contact Lenses

April 7, 2011
2:00-4:00 PM, Lecture Hall 1A
George Spueh, MD
Professor of Ophthalmology
Jefferson University School of Medicine
Compassionate Care of the Glaucoma Patient

May 19, 2011
2:00-4:00 PM, Lecture Hall 1A
Michael S. Ip, MD
Associate Professor of Ophthalmology
University of Wisconsin School of Medicine
Retina 1 & Retina 2

June 2, 2011
Annual Alumni Meeting
8:00 AM-4:00 PM, LICh Avram Auditorium
Brandon Ayres, MD
Assistant Surgeon, Cornea Service
Wills Eye Institute

Neil M. Bressler, MD
The James P. Gills Professor of Ophthalmology
Chief of Retina Division, Wilmer Eye Institute
Johns Hopkins School of Medicine

Scott M. Goldstein, MD
Clinical Assistant Professor
Wills Eye Institute
Thomus Jefferson School of Medicine

Jayne S. Weiss, MD
Professor and Chairman, Ophthalmology
Louisiana State University School of Medicine

June 23, 2011
2:00-4:30 PM, Lecture Hall 1A
Sohan Singh Hayreh, MD, MS, PhD, FRCS, FRCOphth, DSc
Professor Emeritus of Ophthalmology
Director, Ocular Vascular Clinic
Department of Ophthalmology & Visual Sciences
University of Iowa College of Medicine
Lecture 1 – CRVO Pearls
Lecture 2 – GCA Pearls
Lecture 3 – ARMD Pearls

August 4, 2011
2:00-4:00 PM, Lecture Hall 1A
Kenneth Rosenthal, MD
Associate Professor of Ophthalmology
University of Utah Medical Center
Lecture 1 – Cataract Surgical Pearls
Lecture 2 – Innovative Eye Surgical Procedures

October 13, 2011
2:00-4:00 PM, Lecture Hall 1A
Leonard B. Nelson, MD
Associate Professor of Pediatrics and Ophthalmology
Jefferson University Medical Center
Co-Director Pediatric Ophthalmology, Wills Eye Institute
Lecture 1 – Misconceptions in Pediatric Ophthalmology
Lecture 2 – The Odyssey of Where We Are in Congenital ET

November 2-3, 2011
Grant T. Liu, MD
Professor of Neurology
University of Pennsylvania School of Medicine
Lecture 2 – Developmental Mechanisms and Disease Therapeutics: A View from the Fly Eye

Grant T. Liu, MD
Professor of Neurology
University of Pennsylvania School of Medicine
Lecture 1 – Developmental Mechanisms and Disease Therapeutics: An Introduction to Glaucoma

November 23, 2011
2:00-3:15 PM, Lecture Hall 1A
Paul D. Langer, MD
Assistant Professor
Institute of Ophthalmology and Visual Science
University of Medicine and Dentistry of New Jersey
Orbital Floor Fractures

November 26, 2011
Caesars Atlantic City Meeting
Full details on www.eyecurrentconcepts.org

VISITING SPEAKER RESEARCH LECTURE SERIES 2011

All research talks will be held 3:00-4:00 PM in Lecture Hall 1A.

February 3, 2011
Ross Cagan, PhD
Professor, Dept. of Developmental and Regenerative Biology
Associate Dean, Graduate School of Biological Sciences
Mount Sinai School of Medicine
Developmental Mechanisms and Disease Therapeutics: A View from the Fly Eye

February 24, 2011
Craig Evinger, PhD
Professor, Neurobiology & Behavior and Ophthalmology
SUNY Stony Brook
Neurobiology of Blepharospasm

March 24, 2011
Marion Gordon, PhD
Associate Professor of Pharmacology & Toxicology
Ernest Mario School of Pharmacy Rutgers University
Pathobiology of Collagen and EMMPRIN in Cornea

May 26, 2011
Ching-Hwa Sung, PhD
Professor, Ophthalmology
Weill Medical College of Cornell University
Retinal pigment epithelium and Retinal Disease

December 8, 2011
2:00-3:15 PM, Lecture Hall 1A
Paul D. Langer, MD
Assistant Professor
Institute of Ophthalmology and Visual Science
University of Medicine and Dentistry of New Jersey
Orbital Floor Fractures

January 6-7, 2012
Caesars Atlantic City Meeting
Full details on www.eyecurrentconcepts.org

June 23, 2011
Terete Borras, PhD
Professor, Ophthalmology
University of North Carolina
Glaucoma Models and Treatment

July 28, 2011
Thomas White, PhD
Associate Professor
Physiology and Biophysics
SUNY Stony Brook
Connexins and Cell Signaling in the Lens

August 25, 2011
Mark Rosenblatt, MD, PhD
Assistant Professor, Weill Cornell Medical Center
Wound Healing in Cornea

September 22, 2011
Janet R. Sparrow, PhD
Associate Professor of Ophthalmic Science and Anatomy and Cell Biology
Columbia University Medical Center
RPE Cell Death

October 27, 2011
John R. Heckenlively, MD
Paul R. Lichter Professor of Ophthalmic Genetics
Professor, Ophthalmology and Visual Sciences
Director, Center for Retinal and Macular Degeneration
University of Michigan Kellogg Eye Center
Retinal Degeneration: A Tale of Mice and Men

December 1, 2011
Simon W. M. John, PhD
Investigator, Howard Hughes Medical Institute
Senior Staff Scientist, The Jackson Laboratory
Research Assistant Professor in Ophthalmology
Tufts University School of Medicine
Mechanistic Insights to Glaucoma Provided by Experimental Mouse Genetics

The entire CME lecture series can be viewed on our website
www.downstate.edu/ophthalmology
Douglas Lazzaro, MD, chairman of SUNY Downstate’s Department of Ophthalmology, says “the retina is an area where there’s tremendous new research activity going on,” much of it featured here.

Downstate now has a director of ophthalmic research, William J. Brunken, PhD, whose investigations into retinal proteins called laminins and netrins may one day help restore sight to the visually impaired. Brahim Chaqour, PhD, investigates the molecular underpinnings of diabetic retinopathy, a microvascular disease that is one of the leading causes of blindness in the United States, all in an effort to develop treatments that may one day prevent the disease.

Gladys Teitelman, PhD, a diabetes researcher who has concentrated mostly on the regeneration of insulin-producing pancreatic beta cells, has widened her investigations to also include diabetic retinopathy. Daniel Rosenbaum, MD, chairman of Downstate’s Department of Neurology, uses the retina as a model for understanding what happens to brain cells during strokes. And Ivan Bodis-Wollner, MD, DSc, director of the Parkinson’s Disease and Related Disorders, Center of Excellence of the National Parkinson Foundation, explores how changes in the retina both signal and influence the development of Parkinson’s disease.

“The research we’re doing at Downstate is leading to new understandings of retinal diseases and the nervous system,” Dr. Lazzaro says. “Most importantly, we’re creating potential new avenues of treatment.”

The retina, the light-sensitive inner layer of the eye, is an area of great scientific significance. Not only does it enable vision, it is an extension of the brain. The retina is composed of neural tissue, much like that larger organ from which it emerges during fetal development. As a result, research into the workings of the retina has a great impact on medical science’s understanding of and treatment of dysfunctions in the brain, as well as in the retina itself.
William J. Brunken, PhD, is keenly interested in the architecture of the eye’s light-sensitive inner layer, the retina. “As an undergraduate,” says Dr. Brunken, an associate professor of anatomy and cell biology, ophthalmology, and neurology, “I got hooked on the retina’s elegantly organized structure. Its columnar organization is very carefully constructed, with a gorgeous symmetry to it.”

Dr. Brunken, director of SUNY Downstate’s division of ophthalmic research, explores the molecular signals that create, maintain, and sometimes deform and destroy that structure.

His investigations into proteins found in the retina’s extracellular matrix, the biological scaffolding that binds its cells together, may lead to treatment breakthroughs for a number of ocular diseases. These include diabetic retinopathy, age-related macular degeneration, and retinitis pigmentosa, a vision-loss problem associated with premature birth. His research may even help restore vision to those whose retinal problems have resulted in blindness.

Dr. Brunken has spent much of his recent career studying two specific retinal proteins, laminins and netrins, which he describes as guidance molecules. “They tell cells where to go and how to function when they get there,” he explains.

Without laminins and netrins, retinal development is disrupted and vision itself may well be impossible. Moreover, laminins and netrins stabilize synapses, the junctions between brain cells across which neural communication takes place, Dr. Brunken says.

The connections between the light-sensitive cells in the retina and the cells that convey visual signals to the brain are held together by laminins, “which are the chief organizers of one of the retina’s, and one of the body’s, most important structures: the basement membrane.”

In a series of papers published in Neuron and the Journal of Neuroscience, Dr. Brunken and his group were the first to demonstrate the presence of native laminins in the central nervous system. Basement membranes in the retina, and elsewhere, serve as platforms onto which cells attach themselves. They also orient tissue development, “telling cells what is top and what is bottom, and therefore how cells should organize themselves,” Dr. Brunken notes. “These properties make them critical for retinal development. If the basement membrane doesn’t form properly, then the attachment of cells is irregular and the retina’s columnar organization, and its ability to transmit visual signals, is lost.”

Dr. Brunken’s lab has identified four of the approximately forty laminin variants that are active in retinal tissue. Mutations in one of the genes that produces the laminin beta-2 protein, a gene called LAMB2, “completely disrupts vasculization of the retina during fetal development,” Dr. Brunken notes. “What results is a very altered pattern of vascularization, much like one sees in children with retinopathy of prematurity, where inflammation and, eventually, the death of retinal tissue, disrupts the visual field.”

Other laminin mutations lead to rare but complex diseases that involve the eye along with other bodily systems. These diseases include Pierson syndrome, Merosin-dependent muscular dystrophy, and Herlitz junctional epidermolysis bullosa.

Dr. Brunken has created a mouse model in which two laminin genes have been removed. These mice have all the symptoms of eye-brain-muscle disease, a complex neurodevelopmental disorder. Of particular interest to Dr. Brunken is the role netrins play in the retina’s organizing structure. “A netrin is nothing more than a small piece of a laminin,” he explains. “Laminins are cross-shaped molecules and netrins are the ends of the arms of the cross.”

Working with Manuel Koch, PhD, of the University of Cologne, in Germany, Dr. Brunken’s lab discovered that a novel type of netrin, called netrin-4, regulates axon guidance in the retina.

“Netrin-4 helps bundle axons in the retina together, enabling communication between the retina and the rest of the brain’s visual apparatus,” Dr. Brunken says. Perhaps most importantly, netrin-4 regulates the branching of the retina’s deepest capillaries.

Understanding the basic functions of these proteins may lead to new treatments for a number of eye diseases, Dr. Brunken says. “If we can separate out those pieces for drug development.”

Dr. Brunken’s investigations may also lead to a new way of treating vision loss from retinal defects. “The hope would be to fool neurons into thinking a silicon chip is a photoreceptor.”

Dr. Brunken explains, “we hope we can interfere with the cell-binding domains—the parts that interact with receptors on cell membranes of molecules—we can use those pieces for drug development.”

Dr. Brunken’s investigations may also lead to a new way of treating vision loss from retinal defects. “Given that laminins and netrins are guidance molecules and stabilize synapses,” Dr. Brunken explains, “we hope we can interfere with the cell-binding domains—the parts that interact with receptors on cell membranes of molecules—we can use those pieces for drug development.”

Dr. Brunken’s investigations may also lead to a new way of treating vision loss from retinal defects. “The hope would be to fool neurons into thinking a silicon chip is a photoreceptor.”

Doc Focuses on Seeing Glaucoma Clearly

The specialist
Dr. John Danias, Professor of Ophthalmology and Cell Biology
Co-Director, Glaucoma Service, SUNY Downstate Medical Center
Director, Glaucoma Service, Long Island College Hospital

A glaucoma specialist for the past 10 years, SUNY Downstate’s Dr. John Danias (formerly at Mount Sinai Medical Center) helps glaucoma patients with every part of their care, including diagnosis, management and surgery.

The big story
July is Glaucoma Awareness Month. So to spotlight the illness, we “check up” with Dr. Danias, who’s been providing care to New York’s own Governor Paterson since his angle closure attack in May.

Who’s at risk
Glaucoma is a disease that affects the optic nerve in the back of the eye, leading to loss of peripheral vision and sometimes the complete loss of vision. It is often associated with high pressure inside the eye.

There are two main forms of glaucoma, open angle glaucoma and closed angle glaucoma. “They’re different diseases,” says Danias. “They both damage the nerve at the back of the eye, but the pathology of the diseases is different.” Open angle glaucoma is more insidious, and closed angle glaucoma is more dramatic in its presentation.

Near-sighted people have a higher risk of developing open angle glaucoma, while farsighted people are more likely to develop closed angle.

For both forms of glaucoma, age is one of the most important risk factors. The disease is almost always diagnosed in people after the age of 60. About 1% of the population aged between 50 and 65 has glaucoma; up to 5% of the total population of people in their 70s and older have glaucoma. Patients with diabetes are also at higher risk of developing glaucoma.

Genes play a big part in glaucoma—so much so that people with a family history of glaucoma are 10 times more likely to develop it themselves. Doctors are working hard to identify the genes that cause glaucoma. “It’s a complex genetic inheritance,” says Danias. “We know some of the genes that cause open angle glaucoma, but they only cause 2% to 3% of the overall cases.”

Signs and symptoms
Patients with angle closure glaucoma are at risk of pressure within their eyes increasing abruptly over a short period of time. “The wall of the eye actually becomes distended from all the pressure,” says Danias. “Patients feel a lot of pain.” The onset of angle closure glaucoma can occur over the course of minutes or hours. The pain can be severe enough to cause headaches, vomiting and blurry vision. Patients are usually aware that something is wrong, and that the source of the problem is in the eye.

Unfortunately, open angle glaucoma often doesn’t show any symptoms until the disease is quite far advanced. “It’s almost asymptomatic,” says Danias, and “people go for years with the disease without noticing. Then they notice problems with their peripheral vision.”

"Glaucoma is not something we know how to prevent," says Danias. "Glaucoma is a chronic disease. We don't have a cure but it's something we can control." If glaucoma is caught early enough, doctors can usually prevent vision loss, or at least slow down the process. Treatment usually consists of some combination of drops, laser surgery and open surgery.

The treatment for open angle glaucoma usually starts with medication in the form of drops. “This treatment is trying to lower the pressure inside the eye,” explains Danias. “The lower the pressure inside the eye, the lower the chance of damage.”

For patients who can’t tolerate drops, there is the option of laser therapy, a 10- to 15-minute procedure done in the office. “The doctor uses the laser to stimulate the cells in the eye that allow the fluid to get out of the eye,” says Danias. The success rate is very high, about 80%.

For angle closure glaucoma, the primary treatment is called laser iridotomy, in which lasers are used to create a passageway for the exit of fluid from the eye. This procedure can be used preemptively for patients at risk of the disease, and has an extremely high success rate of 95%. In a small percentage of cases, when the disease is severe and laser iridotomy fails, the next step is an open surgery done manually by the doctor to open a new passageway.

Research breakthroughs
At Downstate, Danias’s lab has been investigating the role of inflammation in causing glaucoma. “Our work indicates that the immune system may be involved,” says Danias. “There might be some sort of misregulation of what we call the innate immunity (a nonadaptive system that protects us from viruses and bacteria), that gets activated somehow in glaucoma and causes damage.” Dr Danias is now working on gene therapy as a potential new avenue of treatment for glaucoma.

Questions for your doctor
A good first question to ask your doctor is “Do I have any of the risk factors for glaucoma?” While Danias spelled out the major risk factors, there are some others—like corneal thickness—that are more complicated and that most patients won’t be able to spot themselves.

If you have high intraocular pressure, ask your doctor how problematic it is: “Can you give me an estimate of what my risk for developing glaucoma is?” If your doctor thinks you are at higher risk, ask how often you should be screened.

What you can do:

Know your family history
Because glaucoma has a genetic component, if your relatives have suffered from the disease, your risk is 10 times higher. Ask about your family’s history, and be prepared to explain it to your doctor.

See a specialist
If you have any of the risk factors, then get the opinion of a glaucoma specialist. Check the American Academy of Ophthalmology website (www.aoa.org), which allows you to search for eye doctors by their subspecialty and your zip code.

Get frequent checkups
Danias recommends that anyone over 40 get an eye exam every two or three years (more often if they’re having problems). After 60, people should get checked every year. Screening consists of a general eye exam, the “eye puff” exam, and often drops to dilate the eyes so the doctor can see the back of the eye. “It’s not a painful process,” says Danias, “and the expense is covered by insurance.”

Know your numbers
Ask for a reading of your intraocular pressure, and keep a log yourself. It’s just one number per visit. While Danias says the log “can be helpful if you’re traveling around or you have to change doctors.”

Like many illnesses affecting the nervous system, Parkinson’s disease is difficult not only to treat but also to monitor. New evidence suggests that the degenerative motor disorder begins in the peripheral nervous system and then works its way to the central nervous system—most importantly, to the brain. Once established there, this disease can cause a host of neurological problems: tremors, motor impairment, communications difficulties, and mental disturbances.

Visual problems were not thought to be part of Parkinson’s disease, however. From the time the illness was first described in the early 1800s, until more than 150 years later, the loss of visual acuity and the difficulty in distinguishing contrast many Parkinson’s patients experience were attributed to other causes, such as aging, cataracts and glaucoma.

But in the late 1970s, Ivan Bodis-Wollner, MD, DSc, professor of neurology and ophthalmology and director of University Hospital’s Parkinson’s Disease and Related Disorders Center, one of the National Parkinson Foundation’s Centers of Excellence, showed that Parkinson’s disease itself can have a negative impact on vision.

In 1976, using electrophysiology—brain-wave monitoring through externally applied electrodes—he was the first to document delayed visual processing in the brains of individuals with Parkinson’s disease. Following that, he used the method again, this time discovering among Parkinson’s patients deficits in contrast-sensitivity—difficulty distinguishing an image from its background.

Importantly, as part of that research, he showed that vision changes in tandem with neurological functioning. “When a patient doesn’t move well,” Dr. Bodis-Wollner explains, “he doesn’t see well.”

Motor problems in Parkinson’s disease are caused by the death of neurons that secrete and process an important neurotransmitter called dopamine. Dr. Bodis-Wollner’s research established that the death of these neurons, called “dopaminergic” cells, is also responsible for Parkinson’s-related visual problems. “With-out dopaminergic cells, dopamine-sensitive cells are deprived of dopamine,” he notes, “and are no longer able to make very important decisions that relate to vision and to motor execution.”

In the late 1990s, intrigued by the role dopaminergic cells play in the vision of Parkinson’s patients, Dr. Bodis-Wollner developed a quantitative description of the relationship between the retina’s dopaminergic and dopamine-sensitive cells. A major advance in the Parkinson’s disease field, the model has been used to predict the retina’s response to new and existing Parkinson’s treatments.

The ability to image the retina may revolutionize the process of evaluating and monitoring the neuronal changes that occur in Parkinson’s disease.

In the last several years, Dr. Bodis-Wollner has employed a new imaging technology called Optical Coherence Tomography (OCT) to detect microscopic changes in the retina. Says Dr. Bodis-Wollner, “the ability to image the retina may revolutionize the process of evaluating and monitoring the neuronal changes that occur in Parkinson’s disease.”

Using OCT, he has been among the first to measure the retinas of individuals with Parkinson’s disease. Often, they are 15 to 20 percent thinner than normal. “This loss may be a major reason why Parkinson’s patients have trouble detecting contrast,” Dr. Bodis-Wollner says. “And we’ve learned that the area of the retina affected in Parkinson’s may impair visual cognition, the ability to respond to and categorize visual images.

Dr. Bodis-Wollner looks forward to furthering this research by acquiring the latest generation OCT equipment. “With these machines, we hope to be able to specify dopaminergic cells, in addition to measuring the retina’s thickness,” he notes. Giving researchers access to cell counts could dramatically alter the course of clinical trials for new Parkinson’s treatments.

Until recently, “investigators have had to rely on clinical observations and wait a minimum of 18 months to discover the impacts of potential neuroprotective treatments on the brain’s dopaminergic pathways and, thus, on disease progression,” Dr. Bodis-Wollner explains. With the detailed counts of retinal dopaminergic cells and information on retinal thinning that advanced OCT equipment can provide, researchers may be able to assess much more quickly and accurately whether a new treatment has arrested neuronal degeneration.

Dr. Bodis-Wollner notes, “OCT should be able to help quite a lot in our quest for neuroprotective agents—agents that can stop the dying-off of dopaminergic cells.” And with that, help stop the progression of Parkinson’s disease itself.

An Eye Into Parkinson’s Disease

Fig 1. The OCT of the retina of a healthy subject (46 years of age). The bottom of the picture represents the outer layers of the eye; the top, the inner layers. The dip, or “valley,” in the center is normal: retinal neurons are pushed to the side to allow light to penetrate to the outer layers, where photo-receptors are located.

Fig 2. The OCT of the retina of a Parkinson’s disease patient (50 years of age). The valleys—top center—represent the loss of neurons in the inner retina, including the nerve cells which transmit visual information to the brain.
Decoding Diabetic Retinopathy

Between 12,000 and 24,000 Americans go blind each year as a result of diabetic retinopathy. Diabetic retinopathy usually develops over several years and has its origins in the body’s poor control of blood sugar levels. At the onset, the tiny blood vessels in the retina begin to swell and leak. Next, some of these vessels close off. Then, as more of them are blocked, the retina sends molecular signals that initiate a frenzied overgrowth of new blood vessels in the retina. In the advanced stages, called proliferative retinopathy, these weakened vessels invade the vitreous gel that fills the eye; when they leak, severe vision loss or blindness results.

To date, a high-tech vision-saving technique called scatter laser surgery can, when administered early, improve the vision of people with diabetic retinopathy. But the procedure has limitations. Often, it can lead to the loss of peripheral vision, and, because new blood vessels continue to grow, the procedure must be repeated.

To develop better treatments for this vision-imparing disease, Braham Chaqour, PhD, an assistant professor of anatomy and cell biology at SUNY Downstate, is decoding the molecular processes that underlie diabetic retinopathy. “My goal is to understand a number of mechanisms that affect blood vessel growth and degeneration,” he says. These include the role of angiogenic factors, which lead to the proliferation of new blood vessel branches, and the role of anti-angiogenic factors, which lead to the destruction of pre-existing blood vessels and the formation of new blood vessel branches.

“A better understanding at the molecular level will help us learn how to control the process, both in the early and later stages of the disease,” he says.

Dr. Chaqour has made great progress towards this goal. He has identified a “small family of genes” that, in the presence of hyperglycemia (high blood sugar levels), plays a crucial role in all phases of diabetic retinopathy. Working in tissue culture and with laboratory animals, he has documented how these genes, normally dormant genes, begin to express themselves in the retina. Their proteins accumulate in the space surrounding blood vessel cells, further exacerbating pericyte death.

That’s not the only role CYR61 and CTGF play in diabetic retinopathy. During the most advanced stage of diabetic retinopathy, their over-expression contributes to the uncontrolled proliferation of new, leaky blood vessels. Dr. Chaqour has concluded. “The proteins these genes express even cause blood vessels to grow into the eye’s vitreous gel, which, under normal conditions, is completely free of blood vessels. There’s no control mechanism in these newly activated genes that allows them to stop.”

Dr. Chaqour’s lab discovered that vasculogenesis, the creation of entirely new blood vessels from stem cells, is promoted by the CYR61 protein as well. Until recently, scientists believed that angiogenesis—the branching off of new blood vessels from existing ones—was the only blood vessel-formation mechanism involved in the disease. In fact, “scientists believed angiogenesis is a protein called MMP-2. "In the normal retina," Dr. Chaqour explains, "there’s almost no MMP-2. But in diabetic animals, CYR61 and CTGF induce expression of MMP-2." The protein destroys the extracellular matrix, the biological scaffolding that stabilizes and connects cells. “This further degrades the pericytes.”

Dr. Chaqour is using these discoveries to develop pharmacological treatments that may derail diabetic retinopathy, even in the absence of tight blood sugar control. “We’re trying,” he says, “to put together recombinant peptides that will interrupt the growth of abnormal blood vessels and allow healthy retinal activity to occur.” Already, Dr. Chaqour and his colleagues developed several compounds, still unnamed, that block the destruct-

tive action of MMP-2. “That’s not enough to stop diabetic retinopathy, yet,” Dr. Chaqour says. “But it’s a start. One day, we may discover a pharmacological treatment that enables patients to avoid the current surgical one.”

Braham Chaqour, PhD

Dr. Chaqour has identified a “small family of genes,” that in the presence of hyperglycemia, plays a critical role in all phases of diabetic retinopathy. Vasculogenesis took place only during embryonic development and then stopped altogether, he says. By exposing stem cells to CYR61 in tissue culture, Dr. Chaqour and his colleagues demonstrated “this protein promotes the process of vasculogenesis involved in diabetic retinopathy.”

Another of his important discoveries is a protein called MMP-2. “In the normal retina,” Dr. Chaqour explains, “there’s almost no MMP-2. But in diabetic animals, CYR61 and CTGF induce expression of MMP-2.” The protein destroys the extracellular matrix, the biological scaffolding that stabilizes and connects cells. “This further degrades the pericytes.”

Dr. Chaqour is using these discoveries to develop pharmacological treatments that may derail diabetic retinopathy, even in the absence of tight blood sugar control. “We’re trying,” he says, “to put together recombinant peptides that will interrupt the growth of abnormal blood vessels and allow healthy retinal activity to occur.” Already, Dr. Chaqour and his colleagues developed several compounds, still unnamed, that block the destructive action of MMP-2. “That’s not enough to stop diabetic retinopathy, yet,” Dr. Chaqour says. “But it’s a start. One day, we may discover a pharmacological treatment that enables patients to avoid the current surgical one.”

Image 1: A well-organized and functional network of blood vessels in the retina of an adult rat.

Image 2: A disorganized and dysfunctional network of blood vessels in the retina of an adult diabetic rat.


Restraining Abnormal Blood Vessel Growth in the Retina

In the United States, almost 21 million people—7 percent of the population—are diabetic. Of these 21 million, an estimated 40 to 45 percent will eventually suffer from diabetic retinopathy, the leading cause of blindness among American adults. Diabetic retinopathy has its origins in poor control of blood sugar levels. In the eye, high levels of circulating blood glucose levels. Arrow indicates area of leakage in the diabetic retina.

When blood vessels of the retina are infused with a red dye, leakage of the dye is found in the retinas of diabetic rats, but not in retinas of rats with normal blood glucose levels. Arrow indicates area of leakage in the diabetic retina.

Dr. Gladys Teitelman and Jennifer Winkler, PhD student.

Blood Vessel Growth in the Retina

But what if unrestrained blood vessel growth, called proliferative retinopathy, could be kept in check with a recombinant molecule administered by injection or through eye drops? That’s the possibility being investigated by Gladys Teitelman, PhD, professor of anatomy and cell biology, and the two members of her lab, graduate student Jennifer Winkler and research scientist Mamdouh Kedees, PhD.

Dr. Teitelman is a diabetes researcher whose primary focus is the regeneration of insulin-producing B-cells in the pancreas. Yet she finds this new avenue of diabetes research and “the possibility that we might be able to intervene in diabetic retinopathy” compelling.

One promising focus involves proteins belonging to the CCN family, including connective tissue growth factor (CTGF), cystein-rich protein (CYR61), and nephroblastoma overexpressed gene (NOV), which play a role in new blood vessel formulation and appear to be involved in the initiation of diabetic retinopathy’s pathological changes.

Dr. Teitelman and her team are specifically focusing on the action of CTGF. “We’re making progress in understanding how we might be able to interrupt its destructive action in the eye,” she says.

Under normal conditions, CTGF is involved in a host of healthy biological processes that include wound healing, cell division and nerve conduction. In the diabetic eye, however, its action can be life altering.

“Because CTGF is involved in so many important biological processes, it’s not a good target for a systemic therapy,” observes Ms. Winkler. “But the eye is encapsulated, which means we can block the action of CTGF in the eye without concern for the treatment’s impact on the rest of the body.”

Working first in tissue culture and then in diabetic laboratory rats, Dr. Teitelman and her team have developed recombinant molecules that bind to CTGF and prohibit its production. In their first experiment, the team used a bioengineered virus that reduced CTGF expression by 70 percent in cells in culture. Now, Dr. Teitelman’s lab is using a small interfering RNA (siRNA) to accomplish the same task in laboratory rats with induced diabetes.

“One of siRNA’s benefits is that it’s very small — about a tenth the size of the virus we engineered,” says Dr. Kedees. The smaller size means any treatment that involves siRNAs will be less likely to provoke immune or inflammatory responses.

Moreover, using siRNAs rather than viruses will facilitate a treatment’s entrance into involved cells, since viruses enter cells through receptors on the cells’ surfaces. During this process, viruses’ relatively large size can hinder their entrance. “siRNA, on the other hand,” Dr. Teitelman says, “is small enough to enter the cell simply through diffusion,” by the natural movement of molecules in the body.

Dr. Teitelman is hopeful the team’s research will result in an effective treatment for what is becoming, in the United States and around the world, an increasingly common illness. “With the first sign of diabetic retinopathy—the presence of leaky blood vessels, for instance—we may be able to intervene and prevent further complications of the disease,” she explains.

Of course, Dr. Teitelman notes, “glycemic control is always important in preventing diabetic retinopathy. But given how hard that is to achieve, we must also pursue research that can lead to effective, minimally invasive treatments.”

Dr. Gladys Teitelman and Jennifer Winkler, PhD student.
Dr. Jeffrey Freedman, an expert in glaucoma and corneal disease, and former director of the glaucoma subspecialty program, has played an important role in the Department of Ophthalmology. During an impressive career spanning almost four decades, Dr. Freedman has made a number of notable contributions in the field of ophthalmology.

Molteno Glaucoma Implant
The Molteno Glaucoma Implant, which is the prototype of all long tube implants in use today, was first introduced into the United States by Dr. Freedman in 1975, and implanted into a patient at SUNY Downstate at that time. It was Dr. Freedman’s work with the FDA that allowed for the subsequent use of glaucoma implants by other surgeons in the United States.

Dr. Freedman described the use of a patch graft over the long tube implants, which is now standard practice for these implants. This procedure was first done at SUNY Downstate by Dr. Freedman in 1985.

Supra-Tenon’s capsule placement of a single-plate Molteno implant
The supra-Tenons implantation of the Molteno implant was developed by Dr. Freedman and first published by him in the *British Journal of Ophthalmology* in 2007.

Ex-PRESS Glaucoma shunt implantation
The use of the Ex-PRESS shunt under a scleral flap was first performed in the USA by Dr. Freedman in 2003.

Glaucoma implants have changed the way we manage complicated glaucoma cases.

Dr. Freedman helped pioneer the use of implantable devices for the treatment of glaucoma, and this remains a primary focus of his clinical practice and research.

Glaucoma Implantation Started at Downstate in the 1970s

Research
Dr. Freedman continues to teach part-time at University Hospital of Brooklyn while also conducting a private practice. His current research projects include studies to identify the most effective anti-fibrosis medications to improve outcomes following glaucoma surgery, as well as efforts to define factors contributing to the development of glaucoma in individuals who have undergone corneal transplantation.

Dr. Freedman serves as chairperson of the Glaucoma Implant Session of the World Glaucoma Congress which occurs every two years.

Dr. Freedman was the Chairperson for the Glaucoma Implant Session at the highly-acclaimed World Congress of Ophthalmology in Australia 2002, and was also invited to chair the session at the World Congress of Ophthalmology in Singapore in 2008 but had to decline due to health reasons.

He was chairperson at the IGS (International Glaucoma Symposium), which is now the World Glaucoma Congress, in Prague 2001, Barcelona 2003, Cape Town 2005, Athens 2007, Singapore 2008, Boston 2009, and now in Paris 2011. He has had virtually the same faculty at all of these meetings.

Implants now serve as part of the surgical armamentarium that the glaucoma surgeon can consider as a management option.

Glaucoma implant devices offer a treatment option for advanced and complicated glaucoma. They are particularly well suited for uveitic glaucoma, failed trabeculectomy, neovascular glaucoma, and some selected primary glaucoma cases.

A new Molteno implant with Freedman modifications is currently in development and expected for use in late 2011 or early 2012.

Dr. Freedman has published over 70 articles in peer-reviewed journals. Following are some recent book chapters he has authored.

2) *Management of Bleb Fibrosis. Glaucoma Complications*. AAO 2010
3) *Glaucoma Surgical Management*, Saunders 2009
4) “Drainage Implants” in *Ophthalmology*, Mosby. 3rd Ed 2009


Our Faculty

Kichiemon Asoma, MD
Clinical Assistant Professor of Ophthalmology
Areas of Expertise:
Cornea & Anterior Segment • Cataract Surgery • Corneal Transplantation • Refractive and LASIK Surgery • Comprehensive Ophthalmology

Ivan Bodis-Wollner, MD, DSc
Professor of Neurology and Ophthalmology
Director, Parkinson's Disease Center of Excellence
Areas of Expertise:
Clinical Neurology • Clinical Neuropathology • Movement Disorders • Parkinson's Disease

William J. Brunken, BS, PhD
Director of Ophthalmic Research
Professor of Ophthalmology and Cell Biology
Areas of Expertise:
Retinal Angiogenesis • Extracellular Matrix • Laminins of the Eye

Brahim Chaquar, PhD
Associate Professor of Cell Biology
Areas of Expertise:
Retinal Angiogenesis • ROP • CCN Proteins

John Danias, MD, PhD
Professor of Ophthalmology and Cell Biology
Co-Director of the Glaucoma Service
Director, Glaucoma Service, LICH
Areas of Expertise:
Glaucoma • Glaucomatous Neurodegeneration • Gene Therapy

James A. Deutsch, MD
Assistant Professor of Ophthalmology
Areas of Expertise:
Pediatric & Adult Strabismus • Pediatric Cataracts • Pediatric Eye Surgery • Amblyopia • Cataract Surgery

Monica Dweck, MD
Assistant Professor of Ophthalmology
Director of Oculoplastics
Vice Chair & Program Director, Residency Program
Areas of Expertise:
Thyroid Ophthalmopathy • Orbital Wall Fractures • Orbital Tumors • Dry Eye • Lid Lacerations

Marcus S. Edelstein, MD, PhD
Clinical Associate Professor of Ophthalmology
Areas of Expertise:
General Ophthalmology • Clinical Optics • Laser Theory • Refractive Surgery • Ophthalmic Infections

Michael P. Ehrenhaus, MD
Assistant Professor of Ophthalmology
Director, Cornea, External Disease & Refractive Surgery
Areas of Expertise:
Intraokuk • Intacs • Cataract Surgery • Corneal Transplant Surgery • Anterior Segment Reconstruction

Jeffrey Freedman, MD, PhD
Clinical Professor of Ophthalmology
Areas of Expertise:
Glaucoma • Corneal Disease • Implantable Devices for the Treatment of Glaucoma

Anthony Girardi, MD, FACS
Clinical Assistant Professor of Ophthalmology
Director, Division of Ophthalmology, Coney Island Hospital
Areas of Expertise:
Comprehensive Ophthalmology • Sutureless Cataract Surgery • Intraclear Lens Implantation

Josh Glatman, MD
Clinical Assistant Professor of Ophthalmology
Areas of Expertise:
Diagnosis and Management of Retinal and Vitreous Disorders • Advanced Vitreo-Retinal Surgery

Lekha Gopal, MD
Clinical Assistant Professor of Ophthalmology
Areas of Expertise:
Comprehensive Ophthalmology • Neuro-Ophthalmology

Himani Goyal, MD
Clinical Assistant Professor of Ophthalmology
Areas of Expertise:
Orbital Tumors • Cataract Surgery • Corneal Transplantation • Refractive Surgery • Ophthalmic Microsurgery

Ashima V. Kumar, MD
Assistant Professor of Ophthalmology
Director of Pediatric Ophthalmology & Strabismus
Areas of Expertise:
Pediatric Ophthalmology • Strabismus Surgery

Douglas R. Lazzaro, MD, FACS, FAAO
Professor and Chair of Ophthalmology
Areas of Expertise:
Advanced Vitreo-Retinal Surgery • Cataract Surgery

E. Clifford Lazzaro, MD
Associate Professor of Clinical Ophthalmology
Retired Chair of Ophthalmology, Lutheran Medical Center
Areas of Expertise:
Comprehensive Ophthalmology • Ophthalmic Surgery

Lois M. McNally, MD, FACS, FAAO, FCAP
Associate Professor of Ophthalmology
Areas of Expertise:
Pediatric Ophthalmology • Ocular Genetics

Maria Musarella, MD
Professor of Ophthalmology
Areas of Expertise:
Pediatric Ophthalmology • Ocular Genetics

Kenneth Olumba, MD
Clinical Assistant Professor of Ophthalmology
Areas of Expertise:
Diabetic Retinopathy • Retinal Detachment • Ocular Trauma • Macular Degeneration

Bradley Phillips, MD
Assistant Professor of Ophthalmology
Areas of Expertise:
Neuro-Ophthalmology • Refractive Surgery • Small-Incision Cataract Surgery

Baljeet Purewal, MD
Assistant Professor of Ophthalmology
Areas of Expertise:
Cosmetic Oculoplastics • Ophthalmic Plastic & Reconstructive Surgery

Shobhit Rastogi, MD
Assistant Professor of Ophthalmology
Co-Director, Glaucoma Service
Areas of Expertise:
Glaucoma • Cataracts • Comprehensive Ophthalmology

Frank Scala, PhD
Professor, Cell Biology and Ophthalmology
Areas of Expertise:
Optic Nerve Regeneration

Wayne Scott, MD
Assistant Professor of Ophthalmology
Areas of Expertise:
Advanced Glaucoma and Cataract Surgery • Management of All Forms of Glaucoma

Osher Sebrow, MD
Clinical Assistant Professor of Ophthalmology
Director, Division of Ophthalmology, Brookdale Hospital
Areas of Expertise:
Contact Lenses • Surface Ablation to Correct Refractive Errors

Roman Shinder, MD
Assistant Professor of Ophthalmology
Areas of Expertise:
General Oculoplastics • Thyroid Ophthalmopathy • Orbital Wall Fractures • Orbital Tumors • Cosmetic Eye Surgery

Eric Shrier, DO
Assistant Professor of Ophthalmology
Director, Retina Service
Areas of Expertise:
Diseases of the Posterior Segment (Vitreous, Retina and Macula)

Edward F. Smith, MD
Clinical Associate Professor of Ophthalmology
Associate Chief of Ophthalmology & Director, Brooklyn VA
Areas of Expertise:
General Ophthalmology • Anterior Segment Surgery • Phacoemulsification for Cataracts • Pterygium

Arthur H. Wolintz, MD
Former Chair and Distinguished Teaching Professor of Ophthalmology
Director, Neuro-Ophthalmology Service (Clinical Affiliates)
Areas of Expertise:
Optic Neuritis • GCA • Cranial Nerve Palsies • Headache
2010 Pfizer Visiting Professorship Awarded to SUNY Downstate Department of Ophthalmology

Drs. Douglas Lazzaro and Monica Dweck with the 2011 Graduating Class

Dr. Sara Hanson in OR with Attending Dr. Kenneth Olumba

Drs. William Brunken and Brahim Chaqour at ARVO 2010

Drs. Harry Flynn, Douglas Lazzaro and Joel Schuman at June 2010 Alumni Meeting at SUNY Downstate

Drs. Sara Ferri, E. Clifford Lazzaro and Baljeet Purewal

Dr. Ramanath Bhandari with Attending Baljeet Purewal, MD

Dr. Douglas Lazzaro, Professor Eberhart Zrenner, MD, and Dr. William Brunken 2010 Pfizer Visiting Professorship Awarded to SUNY Downstate Department of Ophthalmology

Drs. Douglas Lazzaro and Monica Dweck with the 2011 Graduating Class

Dr. Sara Hanson in OR with Attending Dr. Kenneth Olumba
SUNY DOWNSTATE MEDICAL CENTER
DEPARTMENT OF OPHTHALMOLOGY

PRESENTS

CURRENT CONCEPTS IN OPHTHALMOLOGY

January 6-7, 2012
Caesars Atlantic City, New Jersey

Visiting Faculty

Anthony J. Aldave, MD  Michael Kazim, MD
Miguel N. Burnier, MD, PhD  Alex V. Levin, MD, MHSc
Donald J. D’Amico, MD  William F. Mieler, MD
Lt. Col. Sheri DeMartelaere, MD  Jonathan Myers, MD
Steven L. Galetta, MD  Alan Sugar, MD
Professor Alon Harris  Joel Sugar, MD
Bonnie An Henderson, MD

For Complete Information or to Register Online, go to
www.eyecurrentconcepts.org

Course limited to 300 attendees
Earn up to 11 CME category 1 credits  Course fee $299.00
Hotel rooms limited - Call (800) 345-7253 and mention “SUNY Downstate”
Questions about the meeting? Call Beatrice Pierre (718) 245-5460

COURSE DIRECTOR:
Douglas R. Lazzaro, MD
Professor and Chairman, Department of Ophthalmology